These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 30993097)

  • 61. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.
    Toyama K; Karasawa M; Yokohama A; Mitsui T; Uchiumi H; Saitoh T; Handa H; Murakami H; Nojima Y; Tsukamoto N
    Intern Med; 2011; 50(21):2557-61. PubMed ID: 22041356
    [TBL] [Abstract][Full Text] [Related]  

  • 62. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [JAK2-V617F mutation in patients with myeloproliferative neoplasms: association with FLT3-ITD mutation].
    Spasovski V; Tosić N; Kostić T; Pavlović S; Colović M
    Srp Arh Celok Lek; 2010; 138(9-10):614-8. PubMed ID: 21180092
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F).
    Zhao L; Ma Y; Seemann J; Huang LJ
    Biochem J; 2010 Jan; 426(1):91-8. PubMed ID: 19929856
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [A novel modi cation of real-time AS-qPCR by using locked nucleic acid-modified oligonucleotide probe as wild type allele amplification blockers for quantitative detection of the JAK2 V617F mutation].
    Shao DH; Liang GW; He ML; Cao QY
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):421-5. PubMed ID: 23688754
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].
    Funakoshi-Tago M
    Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
    Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
    Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
    [TBL] [Abstract][Full Text] [Related]  

  • 69. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871
    [TBL] [Abstract][Full Text] [Related]  

  • 70. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
    da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

  • 72. JAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary Myelofibrosis.
    Xia J; Lu MZ; Jiang YQ; Yang GH; Zhuang Y; Sun HL; Shen YF
    Chin J Cancer Res; 2012 Mar; 24(1):72-6. PubMed ID: 23359764
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Correlation between JAK2-V617F mutations and variation of peripheral blood cells among BCR/ABL-negative MPD patients].
    Ye YX; Song XB; Zhou Y; Ying BW; Lu XJ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Oct; 29(5):582-6. PubMed ID: 23042399
    [TBL] [Abstract][Full Text] [Related]  

  • 74. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
    Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
    Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.
    Lippert E; Boissinot M; Kralovics R; Girodon F; Dobo I; Praloran V; Boiret-Dupré N; Skoda RC; Hermouet S
    Blood; 2006 Sep; 108(6):1865-7. PubMed ID: 16728702
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.
    Kralovics R; Teo SS; Li S; Theocharides A; Buser AS; Tichelli A; Skoda RC
    Blood; 2006 Aug; 108(4):1377-80. PubMed ID: 16675710
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
    Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
    Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
    [TBL] [Abstract][Full Text] [Related]  

  • 78. JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
    Leuk Lymphoma; 2006 Feb; 47(2):313-4. PubMed ID: 16321863
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Somatic mutation of the V617F JAK2 gene in patients of the cardiovascular diseases].
    Olkhovskiy IA; Gorbenko AS; Stolyar MA; Grischenko DA; Tkachenko OA; Martsinkevich TL
    Ter Arkh; 2019 Jul; 91(7):25-28. PubMed ID: 32598732
    [TBL] [Abstract][Full Text] [Related]  

  • 80. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.
    Barosi G; Bergamaschi G; Marchetti M; Vannucchi AM; Guglielmelli P; Antonioli E; Massa M; Rosti V; Campanelli R; Villani L; Viarengo G; Gattoni E; Gerli G; Specchia G; Tinelli C; Rambaldi A; Barbui T;
    Blood; 2007 Dec; 110(12):4030-6. PubMed ID: 17712047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.